Zimmer Biomet (ZBH) Q4 2025 earnings review
Top-Line Acceleration Meets Bottom-Line Friction
Zimmer Biomet closed 2025 with strong momentum, posting 10.9% reported revenue growth (5.4% organic) as the Paragon 28 acquisition fueled the S.E.T. segment. However, the growth story is becoming expensive. Adjusted EPS grew only 4.8%—less than half the rate of revenue—indicating significant margin compression. Looking ahead, management announced a major strategic pivot to a direct sales model in the U.S., a move they admit contributes to a lukewarm FY26 guidance ($8.30-$8.45 EPS), implying barely 2% earnings growth at the midpoint.
🐂 Bull Case
The legacy business is performing exceptionally well. Knees grew 6.9% and Hips 4.9% organically in Q4, accelerating from earlier in the year. The 'Magnificent Seven' product cycle (including Persona OsseoTi and Z1 stems) is clearly taking market share.
With the Paragon 28 acquisition integrated, the Board authorized a new $1.5 billion share repurchase program. $250M was already deployed in Q4, signaling confidence in cash flow generation ($1.17B Free Cash Flow for FY25).
🐻 Bear Case
Management announced a transition to a 'predominantly direct' sales organization in the U.S. While strategically sound long-term, these transitions historically cause near-term disruption, sales dis-synergies, and increased SG&A. Guidance for FY26 already reflects this 'tempering.'
While the S.E.T. segment grew 20% reported, organic growth was a sluggish 2.9%—significantly lagging the company average. Without the inorganic boost from Paragon 28, this high-potential segment is underperforming the core recon business.
⚖️ Verdict: ⚪
Neutral. The core organic growth in Knees and Hips is the best we've seen in years, but the company is entering a 'hard' year. The shift to direct sales in the U.S. combined with meager 2026 earnings guidance (implied ~2% growth) suggests a transition period rather than an immediate breakout.
Key Themes
The 'Paragon Effect' Masking S.E.T. Weakness
The Sports, Extremities, and Trauma (S.E.T.) segment posted a massive 20.1% reported growth number. However, this is largely an M&A illusion. Organic constant currency growth for S.E.T. was only 2.9%, making it the slowest-growing major segment. The integration of Paragon 28 is driving the headline number, but the underlying legacy S.E.T. business is dragging on the portfolio.
Knees Segment Accelerating
The Knee business is the standout performer, accelerating to 6.9% organic growth in Q4 (up from 1.9% in Q1). This confirms traction for the Persona OsseoTi and ROSA robotics platform. In the U.S., where competition is fiercest, Knees grew 6.0%, proving ZBH is successfully defending and expanding its fortress segment.
Sales Model Disruption
The announcement to transition the U.S. sales force to a direct model is a high-risk operational pivot. Management explicitly noted this 'tempers our 2026 sales guidance.' Moving away from distributors usually involves buyout costs, potential inventory destocking by exiting distributors, and relationship friction with surgeons loyal to specific reps.
Innovation Pipeline
Beyond M&A, R&D is delivering. The company performed the world's first iodine-treated hip procedure in Japan (targeting infection prevention) and received clearance for the ROSA Knee with OptimiZe. These 'Magnificent Seven' products are critical to sustaining the ASP pricing power required to offset volume pressures.
EPS Dilution Persists
Despite a double-digit revenue jump (+10.9%), GAAP Net Income fell 41.7% and Adjusted EPS rose only 4.8%. The divergence highlights the cost of the Paragon 28 integration, interest expenses, and potentially lower-margin mix. The leverage simply isn't there yet.
Other KPIs
Stable. Cash generation remains a bright spot, allowing for $250M in share repurchases in Q4 and a new $1.5B authorization. Free Cash Flow finished at $1.17B for the year.
Solid, though trailing the U.S. (+5.7%). Currency headwinds remain a factor, with reported international growth at 10.6% vs 6.6% constant currency. The divergence between constant currency and reported shows FX is shifting from a headwind to a tailwind in the quarter.
Accelerating. Up from +3.8% in Q3. The U.S. Hips business was particularly strong at +7.9% reported, driven by the Z1 hip stem and new launches.
Guidance
Decelerating. This compares to 7.2% reported growth in FY25. The guidance reflects the 'tempering' due to the U.S. sales organization transition and the lapping of the Paragon 28 acquisition anniversary in April 2026.
Stagnating. The midpoint ($8.375) implies only ~2.1% growth over FY25's $8.20. This is a disappointment for investors looking for margin expansion after a year of heavy integration.
Decelerating. FY25 organic growth finished at 3.9%. The guide for 1-3% organic suggests significant disruption from the sales force changes or a conservative stance on market volume.
Key Questions
Direct Sales Transition Costs
Management mentioned the U.S. sales transition 'tempers' revenue, but what is the impact on SG&A? Are there one-time buyout costs or dis-synergies baked into the flat EPS guidance?
S.E.T. Organic Drag
With organic S.E.T. growth at 2.9% lagging the portfolio, when will the cross-selling synergies from Paragon 28 actually materialize to lift the core segment?
2026 Margin Profile
Revenue is guided up ~3.5% at the midpoint, but EPS is up only ~2%. Why is operating leverage negative in 2026 despite the 'synergies' from recent acquisitions and cost programs?